Assenagon Asset Management
AMRX icon

Assenagon Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Assenagon Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.3M Sell
2,445,549
-621,812
-20% -$8.52M 0.05% 263
2026
Q1 		$38.1M Sell
3,067,361
-694,378
-18% -$9.32M 0.06% 241
2025
Q4 		$47.4M Buy
3,761,739
+1,611,698
+75% +$18.4M 0.07% 222
2025
Q3 		$21.5M Buy
2,150,041
+1,401,190
+187% +$12.6M 0.03% 353
2025
Q2 		$6.06M Sell
748,851
-70,885
-9% -$534K 0.01% 540
2025
Q1 		$6.87M Buy
819,736
+59,267
+8% +$495K 0.01% 485
2024
Q4 		$6.02M Sell
760,469
-444,525
-37% -$3.73M 0.01% 644
2024
Q3 		$10M Buy
1,204,994
+642,065
+114% +$5.02M 0.02% 535
2024
Q2 		$3.57M Buy
562,929
+16,392
+3% +$104K 0.01% 728
2024
Q1 		$3.31M Buy
546,537
+399,492
+272% +$2.25M 0.01% 714
2023
Q4 		$893K Sell
147,045
-368,188
-71% -$1.64M ﹤0.01% 1126
2023
Q3 		$2.17M Buy
515,233
+283,524
+122% +$1.06M 0.01% 824
2023
Q2 		$718K Sell
231,709
-36,958
-14% -$78.7K ﹤0.01% 1053
2023
Q1 		$373K Buy
268,667
+196,089
+270% +$390K ﹤0.01% 1267
2022
Q4 		$144K Buy
+72,578
New +$163K ﹤0.01% 1325
2021
Q4 		– Sell
-29,517
Closed -$158K – 1417
2021
Q3 		$158K Hold
29,517
– – ﹤0.01% 1247
2021
Q2 		$151K Sell
29,517
-214,883
-88% -$1.22M ﹤0.01% 1162
2021
Q1 		$1.65M Sell
244,400
-3,325
-1% -$18.4K 0.01% 759
2020
Q4 		$1.13M Buy
247,725
+229,125
+1,232% +$1.02M ﹤0.01% 707
2020
Q3 		$72K Sell
18,600
-626,720
-97% -$2.68M ﹤0.01% 1091
2020
Q2 		$3.07M Buy
+645,320
New +$2.66M 0.02% 459
2020
Q1 		– Sell
-34,064
Closed -$164K – 776
2019
Q4 		$164K Sell
34,064
-300,923
-90% -$1.05M ﹤0.01% 735
2019
Q3 		$971K Buy
+334,987
New +$1.17M 0.01% 561

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Assenagon Asset Management's AMRX Position: Q2 2026 in Review

Assenagon Asset Management reduced its Amneal Pharmaceuticals (AMRX) stake by 20% in Q2 2026, selling an estimated $8.52M and leaving 2,445,549 shares worth $42.3M. The position accounts for 0.05% of the portfolio, ranked #263.

Assenagon Asset Management first reported a position in AMRX in Q3 2019 and has held it in 23 quarters since. The position peaked at $47.4M in Q4 2025. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Assenagon Asset Management held 2,445,549 shares of Amneal Pharmaceuticals worth $42.3M as of Q2 2026.
  • Assenagon Asset Management sold 621,812 Amneal Pharmaceuticals shares in Q2 2026, an estimated $8.52M.
  • Amneal Pharmaceuticals made up 0.05% of Assenagon Asset Management's portfolio in Q2 2026, its #263 holding.
  • Assenagon Asset Management first reported a position in Amneal Pharmaceuticals in Q3 2019 and has held it in 23 quarters since.
  • Assenagon Asset Management's Amneal Pharmaceuticals position peaked at $47.4M in Q4 2025.
  • 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.